Navigation Links
Patient Advocates File FOIA Request to FDA on Avastin

WASHINGTON, April 27, 2011 /PRNewswire/ -- Leaders in the battle with the U.S. Food and Drug Administration to retain metastatic breast cancer (mbc) as an indication for the drug Avastin today filed a Freedom of Information Act ("FOIA") request with the FDA.

The filers include noted attorney David Rivkin, partner at the law firm Baker Hostetler (, Frank Burroughs and Steven Walker on behalf of the Abigail Alliance for Better Access to Developmental Drugs ( campaigners for increased access to experimental drugs and Terrence Kalley on behalf of Freedom of Access to Medicines (, an organization dedicated to the right of women to retain Avastin as a medical option for mbc.

The filers are troubled by many actions of the FDA in its review of the drug Avastin, a drug relied upon by an estimated 17,500 women with incurable mbc.  Forty thousand American women die each year from metastatic breast cancer.  Many woman and their oncologists report great success with the drug, yet the FDA will remove the indication for mbc, subject to a final appeal by the drug's manufacturer on June 28th & 29th at the FDA's headquarters in Silver Spring, Maryland.

The FOIA request includes documents regarding the nominations, appointment, actions and communications of the Oncologic Drugs Advisory Committee (ODAC) that will hear the appeal. Even though this panel will render a life and death decision at the June hearings, no patients or their advocates are allowed to speak and many may not be able to attend as the FDA claims space limitations.

The FOIA request also seeks documents regarding the processes by which the FDA reached its conclusions regarding Avastin, the communications between the FDA and various outside parties, any discussions related to the costs of Avastin in the FDA review process, conflicts of interest by those party to the Avastin decision, and other relevant issues.

The filers also seek the scientific basis for the FDA's decision with document requests related to risk and benefit evaluation of Avastin, comparison of the risk / benefit of Avastin versus current approved drugs, the use of progression free survival as a primary end point in cancer drug evaluation and the FDA's criteria for evaluation of toxicity under its Accelerated Approval Process.

The European Medicines Agency's advisory board recommended on April 15th, 2011 expanded use for Avastin for mbc. This follows the National Comprehensive Cancer Network's (an organization of leading U.S. cancer centers treating 160,000 patients per year) second vote to confirm retaining Avastin for use with mbc. The FOIA request includes documents related to how the FDA's decision-making process reached the opposite conclusion on Avastin from these bodies.    

CONTACT:  Rachel Partain, +1-248-404-0722,

SOURCE Freedom of Access to Medicines
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for Asthma or Allergies without Trying First-Line Medications End Up Staying on the Medication
2. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
3. LATEST Medical Introduces New Kind of Patient Information Web Site -
4. TeleTrackings Patient Flow Dashboard XT™ Stops Operational Problems Before They Start
5. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
6. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
7. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
8. Digital Assent Signs 100th PatientPad® Customer
9. Banner Health and Poudre Valley Health System Collaborate to Improve Patient Care in Northern Colorado
10. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
11. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Post Your Comments:
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
Breaking Medicine News(10 mins):